What caused the sudden jump in RGS.AX stock pre-market?

The pre-market jump was driven by heavy volume and renewed interest in Regeneus clinical milestones. No formal ASX release was live at the time, so traders should verify any company announcement on the Regeneus investor page or ASX before trading.

How does Meyka AI rate RGS.AX and what is the forecast?

Meyka AI rates RGS.AX **65.04/100**, Grade B (HOLD). Meyka AI's forecast model projects **A$0.025**, implying **108.33%** upside versus the current **A$0.012**. Forecasts are model-based and not investment guarantees.

Is RGS.AX stock suitable for long-term investors?

Regeneus is a clinical-stage biotech with negative EPS, low cash per share and a current ratio **0.28**. It suits risk-tolerant investors focused on clinical outcomes, not defensive long-term holders without diversification and due diligence.

What short-term trading levels should I watch for RGS.AX?

Key intraday support is near **A$0.01** and resistance near the year high **A$0.02**. Watch relative volume (**6.93x**) and tight stop-loss levels given elevated spreads and volatility.

AU Stocks

RGS.AX Regeneus Ltd (ASX) up 33% pre-market 04 Mar 2026: heavy volume, key signals

ByHuzaifa Zahoor March 3, 2026March 3, 2026

RGS.AX stock opened the pre-market session sharply higher after a surge in trade volume, trading at A$0.012 up 33.33% on heavy flows. Regeneus Ltd (RGS.AX) on the ASX saw 4,275,678 shares trade versus an average of 616,955, a 6.93x relative volume that marks it a high volume mover on 04 Mar 2026. The jump follows renewed investor attention to clinical-stage milestones and biotech sector rotation in Australia. We summarise the drivers, valuation, technicals and an analyst-style forecast to help traders and investors decide next steps.